<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Kidney disease in sarcoidosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Kidney disease in sarcoidosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Kidney disease in sarcoidosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gabriel Choukroun, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H215467823">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically important kidney involvement occasionally occurs in sarcoidosis. Kidney manifestations include interstitial nephritis with or without granuloma formation, and nephrocalcinosis and/or nephrolithiasis resulting from abnormal calcium homeostasis. The classic kidney lesion is noncaseating granulomatous interstitial nephritis. However, hypercalciuria and hypercalcemia are most often responsible for clinically significant kidney disease. Glomerular disease, obstructive uropathy, and end-stage kidney disease (ESKD) may also occur but are uncommon [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The kidney manifestations of sarcoidosis will be reviewed here. General issues related to sarcoidosis and its pathogenesis are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">
          "Pathology and pathogenesis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence and prevalence of kidney involvement in sarcoidosis remain uncertain [
         <a href="#rid3">
          3
         </a>
         ]. The reported prevalence ranges widely due to the variation in study design and enrolled patient populations and due to the heterogeneity and often asymptomatic nature of kidney disease.
        </p>
        <p>
         Several small series have suggested that kidney involvement (as defined by either histologic changes in the kidney or a decline in kidney function in the absence of a biopsy) occurs in approximately 10 to 50 percent of patients with sarcoidosis [
         <a href="#rid4">
          4-8
         </a>
         ], although the disease may be silent and undetected for many years (or forever). A large study examining more than 1200 hospitalized patients with sarcoidosis reported that kidney manifestations were present in approximately 6 percent of cases [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Several studies have examined the relative prevalence of the various kidney lesions related to sarcoidosis: the most common manifestations include interstitial nephritis, nephrolithiasis, and nephrocalcinosis [
         <a href="#rid1">
          1,6,10-12
         </a>
         ]. In one study that reported kidney biopsy results from 27 patients with sarcoidosis and kidney disease, nongranulomatous or granulomatous tubulointerstitial nephritis was observed in 74 percent and nephrocalcinosis was observed in 11 percent [
         <a href="#rid13">
          13
         </a>
         ]. Patients who have interstitial nephritis also may have nephrolithiasis or nephrocalcinosis [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Tubulointerstitial nephritis'
         </a>
         below and
         <a class="local">
          'Kidney stones'
         </a>
         below and
         <a class="local">
          'Nephrocalcinosis'
         </a>
         below.)
        </p>
        <p>
         Sarcoidosis-associated glomerular involvement (such as membranous nephropathy, focal segmental glomerulosclerosis, immunoglobulin A (IgA) nephropathy, and crescentic glomerulonephritis) and other kidney manifestations of sarcoid (such as granulomatous kidney masses or urinary tract obstruction due to retroperitoneal lymph node involvement, retroperitoneal fibrosis, or direct ureteral involvement) are rare. (See
         <a class="local">
          'Uncommon causes'
         </a>
         below and
         <a class="local">
          'Other kidney manifestations'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H21989308">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of inflammation and granuloma formation that leads to interstitial nephritis in sarcoidosis is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">
          "Pathology and pathogenesis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
         Hypercalciuria with or without hypercalcemia in many patients with sarcoidosis may cause nephrocalcinosis and/or nephrolithiasis. Intestinal hyperabsorption of dietary calcium occurs in up to 50 percent of cases of sarcoidosis [
         <a href="#rid1">
          1
         </a>
         ]. The excess calcium leads to hypercalciuria in approximately 40 percent of cases and to hypercalcemia in 2 to 20 percent [
         <a href="#rid1">
          1,2,15-17
         </a>
         ].
        </p>
        <p>
         This abnormality in calcium homeostasis is not limited to sarcoidosis, as it occurs in many other chronic granulomatous diseases. The defect in these disorders is increased production of calcitriol (1,25 dihydroxyvitamin D, the most active metabolite of vitamin D) by activated mononuclear cells (particularly macrophages) in granulomas, the lung, and lymph nodes. Increased calcitriol production appears to be due both to markedly enhanced activation and production of 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D to calcitriol, and inadequate feedback inhibition, which normally limits enzyme expression [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/841.html" rel="external">
          "Hypercalcemia in granulomatous diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1006719912">
         <span class="h1">
          IMPAIRED KIDNEY FUNCTION
         </span>
        </p>
        <p class="headingAnchor" id="H1262883888">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoid-related kidney disease should be considered in all patients with sarcoidosis who present with acute kidney injury (AKI) or chronic kidney disease (CKD). It should also be considered in all patients with AKI or CKD who have hypercalcemia (or serum calcium levels at the higher end of the reference range); most other causes of AKI or CKD are associated with low-normal serum calcium levels because of decreased kidney calcitriol production.
        </p>
        <p>
         Because AKI and/or CKD in patients with sarcoidosis is not always due to sarcoidosis, patients should be evaluated thoroughly for other causes of kidney function impairment, using the same approach as that for patients without sarcoidosis. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">
          "Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/102837.html" rel="external">
          "Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"
         </a>
         .)
        </p>
        <p>
         The targeted laboratory and imaging studies routinely obtained in all patients with newly identified CKD or AKI usually detect or suggest sarcoid-associated kidney disease. As examples, a kidney ultrasound is an effective means of identifying nephrocalcinosis, and urine studies showing sterile pyuria without heavy proteinuria suggest interstitial nephritis.
        </p>
        <p class="headingAnchor" id="H2273273583">
         <span class="h2">
          Common causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nephrocalcinosis is a significant cause of CKD in patients with sarcoidosis [
         <a href="#rid1">
          1,8,19
         </a>
         ]. Sarcoid-related interstitial nephritis can cause AKI and/or CKD, depending on the severity and course of kidney inflammation.
        </p>
        <p class="headingAnchor" id="H2645841539">
         <span class="h3">
          Nephrocalcinosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoid is one of many causes of nephrocalcinosis. Nephrocalcinosis has been reported in between 5 and 13 percent of patients with sarcoidosis [
         <a href="#rid8">
          8,10
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations and diagnosis
         </strong>
         – Nephrocalcinosis is generally asymptomatic and slowly progressive. Patients may present only with an elevated creatinine and benign urinalysis, with or without hypercalcemia. Some patients also may have nephrolithiasis and/or polyuria due to hypercalciuria [
         <a href="#rid20">
          20
         </a>
         ]. The diagnosis of nephrocalcinosis is usually made with kidney imaging (preferably ultrasound or computed tomography [CT]), though it is also apparent on kidney biopsy. The clinical presentation and diagnosis of nephrocalcinosis are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7209.html" rel="external">
          "Nephrocalcinosis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7209.html" rel="external">
          "Nephrocalcinosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation after diagnosis
         </strong>
         – Because nephrocalcinosis has multiple causes, it should be attributed to sarcoidosis only after the demonstration of hypercalcemia and/or hypercalciuria and excessive 1-alpha-hydroxylase activity (ie, elevated serum levels of 1,25 dihydroxyvitamin D with low or low-normal levels of parathyroid hormone). The evaluations of hypercalcemia, if present, and nephrocalcinosis are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/836.html" rel="external">
          "Diagnostic approach to hypercalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7209.html" rel="external">
          "Nephrocalcinosis", section on 'Subsequent evaluation for underlying causes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         –
         <strong>
         </strong>
         Interventions to delay or stop the progression of sarcoid-mediated nephrocalcinosis
         <strong>
         </strong>
         are generally the same as those used to prevent recurrent sarcoid-mediated nephrolithiasis and depend on the presence or absence of hypercalcemia. However, for patients with nephrocalcinosis who have neither hypercalcemia nor recurrent kidney stones, we generally do not use pharmacologic agents to inhibit excess production of 1,25 dihydroxyvitamin D; in these patients the risks of such therapy outweigh potential benefits. (See
         <a class="local">
          'Kidney stones'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with nephrocalcinosis, data to support specific measures that increase the solubility of urinary calcium phosphate or calcium oxalate (eg, increased fluid intake to increase urine volume) are extrapolated from studies of patients with kidney stones (see
         <a class="local">
          'Kidney stones'
         </a>
         below). The general management of CKD, regardless of cause, is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1780762221">
         <span class="h3">
          Tubulointerstitial nephritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interstitial nephritis occurs in approximately 20 percent of patients with sarcoidosis [
         <a href="#rid11">
          11
         </a>
         ]. However, kidney function impairment is not always present  (
         <a class="graphic graphic_picture graphicRef67591" href="/z/d/graphic/67591.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid2">
          2,21-24
         </a>
         ]. As an example, a survey of all kidney biopsies over a six-year period at three general hospitals found clinically significant sarcoid granulomatous interstitial nephritis in only four cases [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4145903998">
         <span class="h4">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoid-related tubulointerstitial nephritis is usually identified in patients with a new diagnosis of sarcoidosis who have diffuse active disease [
         <a href="#rid14">
          14,21,25-27
         </a>
         ]; interstitial nephritis infrequently develops among patients with a longstanding history of sarcoidosis [
         <a href="#rid14">
          14
         </a>
         ]. Many patients with interstitial nephritis have advanced CKD at presentation [
         <a href="#rid14">
          14
         </a>
         ]. These clinical features are illustrated by a retrospective review of 47 patients with biopsy-proven interstitial nephritis (37 with noncaseating granulomas and 10 with interstitial nephritis without granulomas) that reported the following [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated serum creatinine when diagnosed with sarcoidosis – 98 percent (n = 46)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 4 or 5 CKD at presentation – 63 percent (n = 29)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms due to extrarenal sarcoidosis involvement at time of kidney diagnosis – 81 percent (n = 38)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thoracic involvement on chest radiograph – 90 percent (n = 42)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic symptoms, including fatigue, weight loss, and fever – 42 percent (n = 20)
        </p>
        <p>
        </p>
        <p>
         The urinary manifestations of interstitial nephritis are relatively nonspecific. The urinalysis is either normal or shows only sterile pyuria or mild proteinuria. In a review of 52 cases of sarcoid-related interstitial nephritis, sterile pyuria, hematuria, glycosuria were identified in 33, 21, and 12 percent, respectively [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Significant proteinuria is uncommon. In a prospective review of 191 sarcoid patients, proteinuria, defined as urine protein-to-creatinine ratio equal to or exceeding 0.3 mg/mg, was found in 7 percent of patients [
         <a href="#rid28">
          28
         </a>
         ]. More than half of these patients had a known risk factor for proteinuria (diabetes, hepatitis B or C infection, human immunodeficiency virus [HIV], systemic lupus erythematosus, or congestive heart failure).
        </p>
        <p class="headingAnchor" id="H177390422">
         <span class="h4">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of sarcoid-related interstitial nephritis should be suspected among patients who have an elevated serum creatinine, a bland urine sediment or sterile pyuria, and either a known diagnosis or characteristic presentation of extrarenal sarcoidosis. Among such patients, an elevated (or high-normal) serum calcium level also is suggestive. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
         A definitive test for sarcoid-associated interstitial nephritis does not exist. The diagnosis requires three elements:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extrarenal manifestations of sarcoidosis (see
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Diagnostic approach'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interstitial nephritis demonstrated by kidney biopsy (see
         <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">
          "Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Histology'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of other etiologies of interstitial nephritis (see
         <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">
          "Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Establishing the cause'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Histology indicative of interstitial nephritis includes normal glomeruli; interstitial infiltration, mostly with mononuclear cells; tubular injury; and, with more chronic disease, interstitial fibrosis. Kidney biopsy findings of noncaseating granulomas in the interstitium are suggestive, but not diagnostic, of sarcoidosis. Granulomas are not seen in all biopsies of patients with sarcoid-associated interstitial nephritis, and they may be seen in other conditions. In one retrospective review of 40 patients with granulomas on kidney biopsy, 20 were due to sarcoidosis, and the remainder resulted from drug reactions (seven cases), tuberculosis (three), granulomatosis with polyangiitis (GPA; two), leprosy (one), mycobacterium avium (one), and Crohn disease (one) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Rarely, patients with sarcoid-associated interstitial nephritis have no extrarenal manifestations of sarcoidosis upon presentation. Thus, all patients who have granulomatous interstitial nephritis detected on biopsy should have a chest radiograph and pulmonary function tests and, if these are nondiagnostic, a high-resolution chest CT scan to evaluate for pulmonary sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2405477021">
         <span class="h4">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with interstitial nephritis, other conditions that must be considered include drug-induced interstitial nephritis, tuberculosis, other mycobacterial infections, GPA, brucellosis, histoplasmosis, tubulointerstitial nephritis with uveitis (TINU) syndrome, and, rarely, Crohn disease [
         <a href="#rid29">
          29-31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">
          "Clinical manifestations and diagnosis of acute interstitial nephritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1649393003">
         <span class="h4">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of sarcoid-associated interstitial nephritis is discussed below. The general management of patients with AKI or CKD, regardless of cause, is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">
          "Overview of the management of acute kidney injury (AKI) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids as first-line therapy
         </strong>
         – For most patients with active tubulointerstitial nephritis due to sarcoidosis, we suggest treatment with glucocorticoids. Patients with irreversible kidney damage (indicated by fibrosis on biopsy) are unlikely to recover kidney function fully; glucocorticoid therapy among such patients is directed at attempting to slow the course of the disease. However, in patients with severe interstitial fibrosis on biopsy (ie, &gt;50 to 75 percent), the risks of immunosuppressive therapy often outweigh the benefits. In patients with active tubulointerstitial nephritis who also have severe fibrosis on biopsy, our approach depends on kidney size as assessed by ultrasound:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with small kidneys (eg, &lt;9 cm), we generally do not treat with immunosuppressive medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients without small kidneys, the decision to treat with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is determined by shared decision-making and is based on the individual patient's comorbidities and risk tolerance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal dosing regimen for and course of glucocorticoid therapy are unclear. We use
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg per day (up to a maximum dose of 80 mg daily) for six to eight weeks, followed by a slow taper thereafter during the next four to five months to a maintenance dose of 10 mg for an additional six to nine months. Relapses can occur in responders if glucocorticoids are tapered too rapidly [
         <a href="#rid23">
          23
         </a>
         ], and some patients need low doses indefinitely. The precise glucocorticoid regimen may also depend on the course of extrarenal disease, though in general glucocorticoid doses used to treat pulmonary sarcoidosis are lower than doses used for kidney sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data to support the use of glucocorticoids for sarcoid-associated interstitial nephritis are limited primarily to case series [
         <a href="#rid14">
          14,32
         </a>
         ]. In a study of 47 patients with kidney sarcoidosis who were treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (with 10 also receiving intravenous [IV] pulse
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ), the following outcomes were observed [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A complete and partial response occurred in 30 and 5 patients, respectively. However, 66 percent of patients had an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         at a median follow-up of 24 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No response was reported in those with &gt;50 percent fibrosis by histologic examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The presence of hypercalcemia on presentation correlated with a complete response to glucocorticoid therapy at one year (odds ratio [OR] 16, 95% CI 1.8-137).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The addition of pulse IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         to oral glucocorticoid regimens does not appear to confer benefit; in a trial that randomly assigned 40 patients with sarcoidosis-associated interstitial nephritis to pulse IV methylprednisolone followed by oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or to oral prednisone alone, kidney outcomes were similar in each group [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications of glucocorticoid therapy
         </strong>
         –
         <strong>
         </strong>
         Systemic glucocorticoid therapy can lead to numerous adverse effects, including osteoporosis, diabetes mellitus, and opportunistic infection. Given that ectopic hydroxylation of vitamin D may occur in sarcoid granulomas, there is concern about using calcium and vitamin D supplements to prevent osteoporosis in such patients [
         <a href="#rid34">
          34-36
         </a>
         ]. However, supplementation with modest doses of calcium and vitamin D, with appropriate monitoring of serum and 24-hour urine calcium, is safe in many patients with sarcoidosis who are treated with glucocorticoids [
         <a href="#rid37">
          37
         </a>
         ]. Our approaches to calcium and vitamin D supplementation, and to diabetes and opportunistic infection, in patients with sarcoidosis who are undergoing glucocorticoid therapy are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative therapies
         </strong>
         – In patients with sarcoidosis-related interstitial nephritis who cannot tolerate or who do not respond to glucocorticoids, alternative therapies that are effective in pulmonary sarcoidosis may be attempted, such as
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, a combination of these drugs, or, as a last resort, tumor necrosis factor antagonists or their biosimilars [
         <a href="#rid38">
          38,39
         </a>
         ]. Effects of these agents on kidney disease are uncertain. (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H736596467">
         <span class="h2">
          Uncommon causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncommon causes of impaired kidney function in patients with sarcoidosis include inflammatory glomerulonephritis, obstruction without kidney stones, and reduced glomerular perfusion due to hypercalcemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glomerulonephritis
         </strong>
         – Patients with sarcoidosis occasionally present with inflammatory glomerulonephritis [
         <a href="#rid40">
          40,41
         </a>
         ], although the mechanism of glomerular injury is not known nor is the relationship to sarcoidosis proven. Patients with glomerulonephritis have significant proteinuria and hematuria (with or without red cell casts), differentiating them from those with interstitial nephritis. The evaluation of inflammatory glomerulonephritis is discussed elsewhere; treatment depends on the cause and is the same in patients with and without sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Glomerulonephritis (hematuria with proteinuria, kidney function impairment, or other manifestations)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study that reported kidney biopsy results in 27 patients with sarcoidosis, 26 percent had IgA nephropathy [
         <a href="#rid13">
          13
         </a>
         ]. Crescentic glomerulonephritis and membranoproliferative glomerulonephritis due to various causes have been reported in patients with sarcoidosis [
         <a href="#rid42">
          42
         </a>
         ], as have cases of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstruction without kidney stones
         </strong>
         – Ureteral obstruction may result from retroperitoneal lymph node involvement, retroperitoneal fibrosis, and direct ureteral involvement by sarcoid [
         <a href="#rid44">
          44-46
         </a>
         ]. Obstructive uropathy due to sarcoidosis may be responsive to glucocorticoids, but invasive urologic decompression or hemodialysis may be required prior to a clinically significant response [
         <a href="#rid2">
          2,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AKI due to hypercalcemia
         </strong>
         – Marked hypercalcemia from any cause, including sarcoidosis, leads to preglomerular arteriolar vasoconstriction [
         <a href="#rid47">
          47
         </a>
         ], which is sometimes severe enough to cause AKI [
         <a href="#rid48">
          48
         </a>
         ]. AKI solely due to severe hypercalcemia usually resolves with treatment. (See
         <a class="medical medical_review" href="/z/d/html/850.html" rel="external">
          "Treatment of hypercalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/841.html" rel="external">
          "Hypercalcemia in granulomatous diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2391303757">
         <span class="h1">
          KIDNEY STONES
         </span>
        </p>
        <p class="headingAnchor" id="H930465884">
         <span class="h2">
          Clinical manifestations and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nephrolithiasis occurs in approximately 1 to 14 percent of patients with sarcoidosis [
         <a href="#rid1">
          1,6,11,12
         </a>
         ]. The stones are usually comprised of calcium oxalate, sometimes mixed with calcium phosphate.
         <strong>
         </strong>
         The clinical presentation and diagnosis of nephrolithiasis are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7366.html" rel="external">
          "Kidney stones in adults: Diagnosis and acute management of suspected nephrolithiasis"
         </a>
         .)
        </p>
        <p>
         Calcium nephrolithiasis may be the presenting feature of sarcoidosis [
         <a href="#rid1">
          1,6,11,12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 618 patients with sarcoidosis, kidney calculi were the first manifestations in 14 (2.2 percent) [
         <a href="#rid49">
          49
         </a>
         ]. In another nine patients who presented with pulmonary involvement, persistent hematuria or pyuria led to the discovery of asymptomatic calculi via ultrasonography or intravenous (IV) pyelography. Thus, 23 patients (3.7 percent) had kidney calculi at presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study, nephrolithiasis was the presenting feature of the disease in 4 percent of 204 consecutive patients with sarcoidosis [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2292544715">
         <span class="h2">
          Evaluation after diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because calcium kidney stones are so common, calcium nephrolithiasis should be attributed to sarcoidosis only after the demonstration of hypercalcemia and/or hypercalciuria with evidence of excessive 1-alpha-hydroxylase activity (ie, elevated serum levels of 1,25 dihydroxyvitamin D with low or low-normal levels of parathyroid hormone). The evaluations of hypercalcemia, if present, and recurrent calcium kidney stones are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/836.html" rel="external">
          "Diagnostic approach to hypercalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7377.html" rel="external">
          "Kidney stones in adults: Evaluation of the patient with established stone disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3458436321">
         <span class="h2">
          Prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of sarcoid-associated kidney stones involves sufficient fluid intake and managing hypercalcemia and/or hypercalciuria.
        </p>
        <p>
         As for all patients with kidney stones, fluid intake should be maintained to produce at least 2 liters of urine per day. Patients with sarcoid-associated stone disease generally should avoid vitamin D supplements, which may increase the abnormal production of 1,25 dihydroxyvitamin D. Other interventions to prevent sarcoid-mediated kidney stone formation
         <strong>
         </strong>
         depend on the presence or absence of hypercalcemia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypercalcemia
         </strong>
         – For patients with hypercalcemia due to sarcoidosis, the primary means of preventing recurrent calcium kidney stones is to lower serum calcium levels; this usually requires treatment with pharmacologic agents that inhibit the excess production of 1,25 dihydroxyvitamin D either by treating granulomatous inflammation (eg, glucocorticoids) or by inhibition of 1-alpha-hydroxylase (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ). Decreasing calcium intake may improve hypercalcemia. The treatment of hypercalcemia in patients with sarcoidosis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/841.html" rel="external">
          "Hypercalcemia in granulomatous diseases", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thiazide diuretics, which are often used to treat recurrent calcium stones due to hypercalciuria, are contraindicated in patients with hypercalcemia and in patients taking pharmacologic agents to control hypercalcemia. These agents lead to calcium retention and can further increase serum calcium levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normocalcemia
         </strong>
         –
         <strong>
         </strong>
         For
         <strong>
         </strong>
         patients without hypercalcemia, dietary interventions to prevent calcium stone recurrence (eg, limiting sodium intake) are the same as those for patients without sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">
          "Kidney stones in adults: Prevention of recurrent kidney stones"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug therapy is generally indicated if the stone disease remains active or if there is insufficient improvement in the 24-hour urine chemistries despite attempted dietary modification. Oral alkali (eg,
         <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">
          potassium citrate
         </a>
         or potassium bicarbonate) and
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         are therapeutic options for patients with low urine citrate and high urine uric acid, respectively; the use of these agents is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">
          "Kidney stones in adults: Prevention of recurrent kidney stones", section on 'Preventive measures for specific stone types'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with sarcoid-mediated stone disease who do not have low urine citrate or high urine uric acid, or who have ongoing stone formation despite appropriate treatment with oral alkali and/or
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         , pharmacologic treatment is directed at lowering urine calcium. Medications used for this purpose include thiazide diuretics and alternative agents as discussed below:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thiazide diuretics
         </strong>
         – Patients with hypercalciuria due to sarcoidosis are at high risk of thiazide-induced hypercalcemia. If a thiazide challenge is pursued in a patient with sarcoidosis, serum calcium levels should be checked one week following, and then every two to three months. The thiazide should be stopped if hypercalcemia develops, and patients with sarcoidosis may not be able to tolerate thiazide dose escalation. Thiazide use for the prevention of calcium stones is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">
          "Kidney stones in adults: Prevention of recurrent kidney stones", section on 'High urine calcium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative agents
         </strong>
         – For patients with sarcoidosis who have recurrent, severe calcium stone disease and do not respond to or tolerate a thiazide diuretic, agents normally reserved for the treatment of sarcoid-mediated hypercalcemia (eg, low-dose glucocorticoids) may be considered as an alternative means of lowering urine calcium. These therapies have adverse side effects and should be discontinued if they do not lower 24-hour urine calcium excretion. These medications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/841.html" rel="external">
          "Hypercalcemia in granulomatous diseases", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Monitoring the response to dietary and/or drug interventions is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">
          "Kidney stones in adults: Prevention of recurrent kidney stones", section on 'Monitoring the response'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H902499024">
         <span class="h1">
          OTHER KIDNEY MANIFESTATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nephrotic syndrome
         </strong>
         –
         <strong>
         </strong>
         Patients with sarcoidosis may present with nephrotic syndrome (eg, heavy proteinuria, hypoalbuminemia, and peripheral edema), although the relationship to sarcoidosis is unknown. The evaluation and treatment of protein losing nephropathies are the same in patients with and without sarcoidosis and are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Proteinuria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">
          "Overview of heavy proteinuria and the nephrotic syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Membranous nephropathy is the most common cause of protein-losing nephropathy in patients with sarcoidosis [
         <a href="#rid51">
          51-53
         </a>
         ], although focal segmental glomerulosclerosis also has been observed [
         <a href="#rid42">
          42
         </a>
         ]. In a study of 26 patients with sarcoidosis who had clinical evidence of glomerular disease, 11 had membranous nephropathy [
         <a href="#rid53">
          53
         </a>
         ]. Phospholipase A2 receptor (PLA2R) antibodies are frequently observed in patients with sarcoidosis and membranous nephropathy [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As in other chronic inflammatory diseases, kidney AA amyloidosis has been reported in patients with sarcoidosis [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney mass
         </strong>
         –
         <strong>
         </strong>
         Granulomatous kidney infiltration rarely may manifest as a kidney mass [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H211462415">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H540095488">
         <span class="h2">
          Risk of end-stage kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         End-stage kidney disease (ESKD) due to sarcoidosis is uncommon. When it occurs, ESKD is due to nephrocalcinosis and/or interstitial nephritis. In the largest observational study, among 47 patients with sarcoidosis-related interstitial nephritis, only two progressed to ESKD (at 15 and 2 years after presentation) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Patients with more severe manifestations of sarcoidosis may be more likely to develop ESKD. In a study of 78 patients with sarcoidosis who required hospitalization due to the disease, 34 had kidney involvement. Of the 34 patients with sarcoid-related kidney disease, eight (24 percent) eventually progressed to ESKD [
         <a href="#rid4">
          4
         </a>
         ]. Risk factors for ESKD included advanced age at the time of kidney disease diagnosis and interstitial fibrosis on kidney biopsy.
        </p>
        <p class="headingAnchor" id="H3237422024">
         <span class="h2">
          Outcomes after kidney transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The outcome of kidney transplantation in patients with sarcoidosis is not well known. The best data are from a retrospective review of 18 patients with sarcoidosis from eight French kidney transplantation centers [
         <a href="#rid58">
          58
         </a>
         ]. In 10 patients, ESKD was due to granulomatous interstitial nephritis; in eight other patients, ESKD was attributed to causes other than sarcoidosis. At the end of a median follow-up of four years, patient and death-censored graft survival was 94 percent.
        </p>
        <p>
         Recurrence of kidney sarcoidosis after transplantation has been described [
         <a href="#rid58">
          58,59
         </a>
         ]. In the French study above, kidney sarcoidosis recurred in 3 of 10 patients [
         <a href="#rid58">
          58
         </a>
         ]. The patients who had kidney recurrence had a lower median estimated glomerular filtration rate (eGFR; 31 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) compared with the entire cohort. Recurrence was observed a median of 13 months after transplantation.
        </p>
        <p class="headingAnchor" id="H3406089238">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Kidney involvement, defined by either histologic changes in the kidney or a decline in kidney function, occurs in approximately 10 to 50 percent of patients with sarcoidosis, though it is often undetected. The most common kidney manifestations of sarcoidosis include nephrocalcinosis, nephrolithiasis, and interstitial nephritis. Sarcoidosis-associated glomerular involvement is rare. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Hypercalciuria with or without hypercalcemia may cause nephrocalcinosis and/or nephrolithiasis and is due to increased production of calcitriol (1,25 dihydroxyvitamin D, the most active metabolite of vitamin D) by activated mononuclear cells (particularly macrophages) in granulomas. The pathogenesis of inflammation and granuloma formation that leads to interstitial nephritis in sarcoidosis is discussed elsewhere. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">
          "Pathology and pathogenesis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired kidney function
         </strong>
         – The most common sarcoid-specific causes of impaired kidney function are nephrocalcinosis, which can cause chronic kidney disease (CKD), and tubulointerstitial nephritis, which can cause CKD or acute kidney injury (AKI) depending on the severity and course of kidney inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial evaluation
         </strong>
         – Patients with sarcoidosis-related AKI or CKD may have hypercalcemia or serum calcium levels in the higher range of normal; by contrast, most other causes of AKI or CKD are associated with low-normal serum calcium levels because of decreased kidney calcitriol production. The targeted laboratory and imaging studies routinely obtained in all patients with newly identified CKD or AKI usually detect or suggest sarcoidosis-associated kidney disease. (See
         <a class="local">
          'Initial evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nephrocalcinosis
         </strong>
         – Nephrocalcinosis is generally asymptomatic and slowly progressive. Patients may present only with an elevated creatinine and benign urinalysis, with or without hypercalcemia. The diagnosis of nephrocalcinosis is usually made with kidney imaging (preferably ultrasound or computed tomography [CT]), though it is also apparent on kidney biopsy. Interventions to delay or stop the progression of sarcoid-mediated nephrocalcinosis
         <strong>
         </strong>
         are generally the same as those used to prevent recurrent sarcoid-mediated nephrolithiasis and depend on the presence or absence of hypercalcemia. (See
         <a class="local">
          'Nephrocalcinosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tubulointerstitial nephritis
         </strong>
         – The diagnosis of sarcoid-related interstitial nephritis should be suspected among patients who have an elevated serum creatinine, a bland urine sediment or sterile pyuria, and either a known diagnosis or characteristic presentation of extrarenal sarcoidosis. The diagnosis requires interstitial nephritis demonstrated by kidney biopsy, exclusion of other etiologies of interstitial nephritis, and extrarenal manifestations of sarcoidosis. For most patients with active tubulointerstitial nephritis due to sarcoidosis, we suggest treatment with glucocorticoids rather than no immunosuppressive therapy or other immunosuppressive agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Tubulointerstitial nephritis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney stones
         </strong>
         – Calcium nephrolithiasis may be the presenting feature of sarcoidosis. Because calcium kidney stones are so common, calcium nephrolithiasis should be attributed to sarcoidosis only in those with hypercalcemia and/or hypercalciuria who have evidence of excessive 1-alpha-hydroxylase activity (ie, elevated serum levels of 1,25 dihydroxyvitamin D with low or low-normal levels of parathyroid hormone). Prevention of sarcoid-associated kidney stones involves sufficient fluid intake and managing hypercalcemia and/or hypercalciuria. (See
         <a class="local">
          'Kidney stones'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – End-stage kidney disease (ESKD) due to sarcoidosis is uncommon. When it occurs, ESKD is due to nephrocalcinosis and/or interstitial nephritis. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2415658991">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Gianfranco Rizzato, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Muther RS, McCarron DA, Bennett WM. Renal manifestations of sarcoidosis. Arch Intern Med 1981; 141:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casella FJ, Allon M. The kidney in sarcoidosis. J Am Soc Nephrol 1993; 3:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BERGER KW, RELMAN AS. Renal impairment due to sarcoid infiltration of the kidney; report of a case proved by renal biopsies before and after treatment with cortisone. N Engl J Med 1955; 252:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorsane I, Zammouri A, Hajji M, et al. [Renal involvement in sarcoidosis: Prognostic and predictive factors]. Nephrol Ther 2022; 18:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LOFGREN S, SNELLMAN B, LINDGREN AG. Renal complications in sarcoidosis; functional and biopsy studies. Acta Med Scand 1957; 159:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebacq E, Desmet V, Verhaegen H. Renal involvement in sarcoidosis. Postgrad Med J 1970; 46:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacSearraigh ET, Doyle CT, Twomey M, O'Sullivan DJ. Sarcoidosis with renal involvement. Postgrad Med J 1978; 54:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lhote R, Annesi-Maesano I, Nunes H, et al. Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort. Eur Respir J 2021; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis 2006; 48:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LONGCOPE WT, FREIMAN DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine (Baltimore) 1952; 31:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzato G. Sarcoidosis in Italy. Sarcoidosis 1992; 9(Suppl 1):145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löffler C, Löffler U, Tuleweit A, et al. Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients. Sarcoidosis Vasc Diffuse Lung Dis 2015; 31:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahévas M, Lescure FX, Boffa JJ, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) 2009; 88:98.
          </a>
         </li>
         <li class="breakAll">
          Hoffbrand BI. The kidney in sarcoidosis. In: Sarcoidosis and Other Granulomatous Disorders, James DG (Ed), Marcel Dekker, New York 1994. p.335.
         </li>
         <li class="breakAll">
          Lower E. Renal sarcoidosis. In: Sarcoidosis, Baughman R (Ed), Taylor &amp; Francis, New York 2006. p.651.
         </li>
         <li class="breakAll">
          Rizzato G. Calcium Metabolism. In: Sarcoidosis, Baughman R (Ed), Taylor &amp; Francis, New York 2006. p.635.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inui N, Murayama A, Sasaki S, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med 2001; 110:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer FR, Adams JS. Abnormal calcium homeostasis in sarcoidosis. N Engl J Med 1986; 315:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Procino G, Mastrofrancesco L, Tamma G, et al. Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study. PLoS One 2012; 7:e33145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer DR, Evans DJ. Renal impairment in sarcoidosis: granulomatous nephritis as an isolated cause (two case reports and review of the literature). Clin Nephrol 1986; 26:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korzets Z, Schneider M, Taragan R, et al. Acute renal failure due to sarcoid granulomatous infiltration of the renal parenchyma. Am J Kidney Dis 1985; 6:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riordan E, Willert RP, Reeve R, et al. Isolated sarcoid granulomatous interstitial nephritis: review of five cases at one center. Clin Nephrol 2001; 55:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2007; 2:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brause M, Magnusson K, Degenhardt S, et al. Renal involvement in sarcoidosis--a report of 6 cases. Clin Nephrol 2002; 57:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson MG, Banerjee D, Hopster D, Cairns HS. Seven cases of granulomatous interstitial nephritis in the absence of extrarenal sarcoid. Nephrol Dial Transplant 2003; 18:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thumfart J, Müller D, Rudolph B, et al. Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. Am J Kidney Dis 2005; 45:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chopra A, Brasher P, Chaudhry H, et al. Proteinuria in sarcoidosis: Prevalence and risk factors in a consecutive outpatient cohort. Sarcoidosis Vasc Diffuse Lung Dis 2017; 34:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaud N, Belenfant X, Stirnemann J, et al. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine (Baltimore) 2007; 86:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bijol V, Mendez GP, Nosé V, Rennke HG. Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution. Int J Surg Pathol 2006; 14:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams AL, Cook WJ. Granulomatous interstitial nephritis secondary to histoplasmosis. Am J Kidney Dis 2007; 50:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rastelli F, Baragetti I, Buzzi L, et al. Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey. Sarcoidosis Vasc Diffuse Lung Dis 2021; 38:e2021017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahevas M, Audard V, Rousseau A, et al. Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial. Nephrol Dial Transplant 2023; 38:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LARSSON LG, LILJESTRAND A, WAHLUND H. Treatment of sarcoidosis with calciferol. Acta Med Scand 1952; 143:281.
          </a>
         </li>
         <li class="breakAll">
          Scadding J, Mitchell D. Treatment. In: Sarcoidosis, Scadding J, Mitchell D (Eds), Chapman and Hall Medical, London 1985. p.578.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamphuis LS, Bonte-Mineur F, van Laar JA, et al. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res 2014; 29:2498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis Vasc Diffuse Lung Dis 2016; 32:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldszer RC, Galvanek EG, Lazarus JM. Glomerulonephritis in a patient with sarcoidosis. Report of a case and review of the literature. Arch Pathol Lab Med 1981; 105:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Uum SH, Cooreman MP, Assmann KJ, Wetzels JF. A 58-year-old man with sarcoidosis complicated by focal crescentic glomerulonephritis. Nephrol Dial Transplant 1997; 12:2703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergner R, Löffler C. Renal sarcoidosis: approach to diagnosis and management. Curr Opin Pulm Med 2018; 24:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auinger M, Irsigler K, Breiteneder S, Ulrich W. Normocalcaemic hepatorenal sarcoidosis with crescentic glomerulonephritis. Nephrol Dial Transplant 1997; 12:1474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraioli P, Montemurro L, Castrignano L, Rizzato G. Retroperitoneal involvement in sarcoidosis. Sarcoidosis 1990; 7:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godin M, Fillastre JP, Ducastelle T, et al. Sarcoidosis. Retroperitoneal fibrosis, renal arterial involvement, and unilateral focal glomerulosclerosis. Arch Intern Med 1980; 140:1240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariano RT, Sussman SK. Sarcoidosis of the ureter. AJR Am J Roentgenol 1998; 171:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M, Peterson L, Berl T. Mechanism of concentrating defect in hypercalcemia. Role of polydipsia and prostaglandins. Kidney Int 1983; 23:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachmeyer C, Belaube N, Loi V, et al. Hypercalcemia and Acute Renal Failure Indicating Peritoneal Sarcoidosis. Am J Med 2021; 134:e571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax 1995; 50:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzato G, Palmieri G, Agrati AM, Zanussi C. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones B, Fowler J. Membranous nephropathy associated with sarcoidosis. Response to prednisolone. Nephron 1989; 52:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydi Z, Ben Dhaou B, Baili L, et al. [Systemic sarcoidosis and membranous glomerulonephritis]. Rev Pneumol Clin 2014; 70:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stehlé T, Joly D, Vanhille P, et al. Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet J Rare Dis 2013; 8:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stehlé T, Audard V, Ronco P, Debiec H. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant 2015; 30:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komatsuda A, Wakui H, Ohtani H, et al. Amyloid A-type renal amyloidosis in a patient with sarcoidosis: report of a case and review of the literature. Clin Nephrol 2003; 60:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamauchi J, Ubara Y, Suwabe T, et al. Long-term preserved renal function of a patient with mass-forming granulomatous interstitial nephritis by biopsy-based steroid therapy. Clin Exp Nephrol 2010; 14:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnet P, Abisror N, Fain O, et al. 18FDG PET for Detecting Renal Granulomatous Localization: Illustration of Granulomatosis With Polyangiitis and Sarcoidosis. J Clin Rheumatol 2021; 27:S559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aouizerate J, Matignon M, Kamar N, et al. Renal transplantation in patients with sarcoidosis: a French multicenter study. Clin J Am Soc Nephrol 2010; 5:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann DM, Fyfe B, Osband AJ, et al. Sarcoidosis within a renal allograft: a case report and review of the literature. Transplant Proc 2013; 45:838.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7186 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7224744" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Renal manifestations of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8507810" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The kidney in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13223979" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Renal impairment due to sarcoid infiltration of the kidney; report of a case proved by renal biopsies before and after treatment with cortisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34756825" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : [Renal involvement in sarcoidosis: Prognostic and predictive factors].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13508097" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Renal complications in sarcoidosis; functional and biopsy studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5481106" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Renal involvement in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/733683" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sarcoidosis with renal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12870722" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Frequency of kidney disease in chronic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33093118" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060009" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Sarcoidosis: the nephrologist's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14899212" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Sarcoidosis in Italy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25591142" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282700" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282700" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282700" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282700" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11403752" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3748084" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Abnormal calcium homeostasis in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22403735" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3802588" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Renal impairment in sarcoidosis: granulomatous nephritis as an isolated cause (two case reports and review of the literature).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4050783" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acute renal failure due to sarcoid granulomatous infiltration of the renal parenchyma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11334315" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Isolated sarcoid granulomatous interstitial nephritis: review of five cases at one center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699417" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Granulomatous interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11863125" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Renal involvement in sarcoidosis--a report of 6 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12543881" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Seven cases of granulomatous interstitial nephritis in the absence of extrarenal sarcoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685521" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32476835" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Proteinuria in sarcoidosis: Prevalence and risk factors in a consecutive outpatient cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505256" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Renal granulomatoses: a retrospective study of 40 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16501836" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17900469" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Granulomatous interstitial nephritis secondary to histoplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34744417" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36066903" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12976018" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment of sarcoidosis with calciferol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12976018" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of sarcoidosis with calciferol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10430755" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24753153" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Calcium and vitamin D in sarcoidosis: is supplementation safe?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687260" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26847093" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6895019" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Glomerulonephritis in a patient with sarcoidosis. Report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9430876" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A 58-year-old man with sarcoidosis complicated by focal crescentic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29965860" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Renal sarcoidosis: approach to diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9249790" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Normocalcaemic hepatorenal sarcoidosis with crescentic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2255783" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Retroperitoneal involvement in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7406624" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Sarcoidosis. Retroperitoneal fibrosis, renal arterial involvement, and unilateral focal glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9798899" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Sarcoidosis of the ureter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6573545" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Mechanism of concentrating defect in hypercalcemia. Role of polydipsia and prostaglandins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34297974" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Hypercalcemia and Acute Renal Failure Indicating Peritoneal Sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7597671" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Nephrolithiasis as a presenting feature of chronic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15281433" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2638568" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Membranous nephropathy associated with sarcoidosis. Response to prednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25459352" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Systemic sarcoidosis and membranous glomerulonephritis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23631446" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25839741" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14579945" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Amyloid A-type renal amyloidosis in a patient with sarcoidosis: report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798972" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long-term preserved renal function of a patient with mass-forming granulomatous interstitial nephritis by biopsy-based steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30946284" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : 18FDG PET for Detecting Renal Granulomatous Localization: Illustration of Granulomatosis With Polyangiitis and Sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20671220" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Renal transplantation in patients with sarcoidosis: a French multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23498832" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sarcoidosis within a renal allograft: a case report and review of the literature.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
